Ghamar Chehreh Mohammad Ebrahim, Vahedi Mohsen, Pourhoseingholi Mohammad Amin, Ashtari Sara, Khedmat Hossein, Amin Mohsen, Zali Mohammad Reza, Alavian Seyed Moayed
Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
Hepat Mon. 2013 May 8;13(5):e7382. doi: 10.5812/hepatmon.7382. Print 2013 May.
There are insufficient data available on utilization and health care costs of non-alcoholic fatty liver disease. The cost data for different health conditions and services is a major gap in Iranian health system. So this study is the primary or first step towards filling this gap.
This study aims to estimate the diagnosis and treatment costs of Non-alcoholic Fatty Liver.
This cross-sectional study was conducted on 528 subjects. The subjects had been diagnosed with non-alcoholic fatty liver. All the subjects had been referred to the Tehran Fatty Liver Clinic, a clinic of the Baqiyatallah Research Center for Gastroenterology and Liver Diseases, in 2009 and they had been observed for 2 years to determine the frequency of health care utilization (physician visit, laboratory tests, medication and cost of sonography). The costs of diagnosis and treatment for each person were estimated in Purchasing Power Parity dollars (PPP$).
The average total cost was 5,043 PPP$ per person in the 2 years of observation. Majority of these 528 patients (87.9%) had a BMI ≥ 25 (kg/m2). Also, 33.9% were diagnosed with comorbid diseases such as Diabetes Mellitus (DM), Coronary Artery Disease (CAD), hypertension (HTN) and hypothyroidism (HYPO).
The results confirmed that the total costs for non-alcoholic fatty liver among the Iranian adult urban population alone exceeded 1 billion PPP$ per year. These costs can be saved or reduced by effective disease management and early prevention.
关于非酒精性脂肪性肝病的医疗利用情况和医疗费用,可用数据不足。不同健康状况和服务的成本数据是伊朗卫生系统的一个主要缺口。因此,本研究是填补这一缺口的首要或第一步。
本研究旨在估算非酒精性脂肪性肝病的诊断和治疗费用。
本横断面研究对528名受试者进行。这些受试者已被诊断为非酒精性脂肪性肝病。所有受试者于2009年被转诊至德黑兰脂肪肝诊所,该诊所是巴基耶塔拉胃肠病和肝病研究中心的一家诊所,对他们进行了2年的观察,以确定医疗利用频率(就诊、实验室检查、用药和超声检查费用)。以购买力平价美元(PPP$)估算每人的诊断和治疗费用。
在2年的观察期内,人均平均总费用为5043 PPP$。这528名患者中的大多数(87.9%)BMI≥25(kg/m2)。此外,33.9%的患者被诊断患有合并症,如糖尿病(DM)、冠状动脉疾病(CAD)、高血压(HTN)和甲状腺功能减退症(HYPO)。
结果证实,仅伊朗成年城市人口中非酒精性脂肪性肝病的总费用每年就超过10亿PPP$。通过有效的疾病管理和早期预防可以节省或降低这些费用。